I agree that this site is using cookies. You can find further informations here.
X
Teppler, Hedy
66  results:
Search for persons X
?
1

Safety and efficacy of doravirine as first-line therapy in ..:

Orkin, Chloe ; Molina, Jean-Michel ; Cahn, Pedro...
The Lancet HIV.  11 (2024)  2 - p. e75-e85 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Efficacy, Safety, and Tolerability of Doravirine/Lamivudine..:

Rungmaitree, Supattra ; Aurpibul, Linda ; Best, Brookie M...
Journal of the Pediatric Infectious Diseases Society.  12 (2023)  12 - p. 602-609 , 2023
Link: https://doi.org/10.1093/..
 
?
3

A Health Literate Patient-focused Approach to the Redesign ..:

Mills, Alexander ; Myers, Laurie ; Raudenbush, Casey...
Pediatric Infectious Disease Journal.  41 (2021)  1 - p. 51-56 , 2021
Link: https://doi.org/10.1097/..
 
?
4

Design of a Phase III immunogenicity and safety study evalu..:

Teppler, Hedy ; Bautista, Oliver ; Flores, Sheryl..
Contemporary Clinical Trials.  105 (2021)  - p. 106403 , 2021
Link: https://doi.org/10.1016/..
 
?
5

Pharmacokinetics and Safety of a Raltegravir-Containing Reg..:

Krogstad, Paul ; Samson, Pearl ; Acosta, Edward P...
Journal of the Pediatric Infectious Diseases Society.  10 (2020)  2 - p. 201-204 , 2020
Link: https://doi.org/10.1093/..
 
?
6

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) V..:

Orkin, Chloe ; Squires, Kathleen E ; Molina, Jean-Michel...
Clinical Infectious Diseases.  , 2020
Link: https://doi.org/10.1093/..
 
?
7

Maternal–Neonatal Raltegravir Population Pharmacokinetics M..:

Lommerse, Jos ; Clarke, Diana ; Kerbusch, Thomas...
CPT: Pharmacometrics & Systems Pharmacology.  8 (2019)  9 - p. 643-653 , 2019
Link: https://doi.org/10.1002/..
 
?
8

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Diso..:

Wong, Alexander ; Goldstein, Deborah ; Mallolas, Josep...
JAIDS Journal of Acquired Immune Deficiency Syndromes.  82 (2019)  4 - p. e47-e49 , 2019
Link: https://doi.org/10.1097/..
 
?
9

Once-daily Doravirine for Initial Treatment of Adults Livin..:

Thompson, Melanie ; Orkin, Chloe ; Molina, Jean-Michel...
Clinical Infectious Diseases.  , 2019
Link: https://doi.org/10.1093/..
 
?
10

LB1. Doravirine/Lamivudine/Tenofovir DF Continues to Be Non..:

Orkin, Chloe ; Squires, Kathleen ; Molina, Jean-Michel...
Open Forum Infectious Diseases.  5 (2018)  suppl_1 - p. S759-S759 , 2018
Link: https://doi.org/10.1093/..
 
?
11

Doravirine dose Selection and 96-Week Safety and Efficacy v..:

Gatell, Jose M ; Morales-Ramirez, Javier O ; Hagins, Debbie P...
Antiviral Therapy.  24 (2018)  6 - p. 425-435 , 2018
Link: https://doi.org/10.3851/..
 
?
12

543. An Integrated Safety Analysis Comparing Once-Daily Dor..:

Thompson, Melanie ; Orkin, Chloe ; Molina, Jean-Michel...
Open Forum Infectious Diseases.  5 (2018)  suppl_1 - p. S201-S202 , 2018
Link: https://doi.org/10.1093/..
 
?
13

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With ..:

Cahn, Pedro ; Sax, Paul E. ; Squires, Kathleen...
JAIDS Journal of Acquired Immune Deficiency Syndromes.  78 (2018)  5 - p. 589-598 , 2018
Link: https://doi.org/10.1097/..
 
?
14

Influence of Sex/Gender and Race on Responses to Raltegravi..:

Squires, Kathleen ; Bekker, Linda-Gail ; Katlama, Christine...
Open Forum Infectious Diseases.  4 (2017)  1 - p. , 2017
Link: https://doi.org/10.1093/..
 
?
15

Baseline HIV-1 resistance, virological outcomes, and emerge..:

Boyd, Mark A ; Moore, Cecilia L ; Molina, Jean-Michel...
The Lancet HIV.  2 (2015)  2 - p. e42-e51 , 2015
Link: https://doi.org/10.1016/..
 
1-15